Advertisement
Advertisement

Read Now: HIV 2014 Year in Review >>

Medical News

Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection

March 16, 2009

"Antiretroviral agents, particularly protease inhibitors (PIs), may adversely affect lipid levels in patients with HIV infection. However, it is not known whether HIV-associated dyslipidemia is more difficult to treat," the researchers explained. Thus, they conducted a retrospective cohort study to compare the effectiveness and safety of lipid-lowering therapy in patients with and without HIV infection.

In an integrated health care delivery system from 1996 to 2005, 829 patients with HIV and 6,941 patients without HIV who began lipid-lowering therapy for elevated low-density lipoprotein cholesterol or triglyceride levels were studied. Percentage change in lipids within 12 months and adverse liver- and muscle-related clinical and laboratory events were monitored.

Compared with HIV-uninfected patients, those with HIV infection beginning statin therapy had smaller reductions in low-density lipoprotein cholesterol levels (25.6 percent vs. 28.3 percent; P=0.001), which did not vary by antiretroviral therapy class. Patients with HIV beginning gemfibrozil therapy had substantially smaller reductions in triglyceride levels than patients without HIV infection (44.2 percent vs. 59.3 percent; P<0.001), and reductions with gemfibrozil varied by antiretroviral therapy class (44.0 percent [P=.0001] in patients receiving PIs only, 26.4 percent [P<0.001] in patients receiving PIs and nonnucleoside reverse transcriptase inhibitors [NNRTIs], and 60.3 percent [P=0.94] in patients receiving NNRTIs only). Rhabdomyolysis was diagnosed in three HIV-infected patients and in one patient without HIV infection. The researchers observed no clinically recognized cases of myositis or myopathy. While the risk for laboratory adverse events was low (<5 percent), it was increased in patients with HIV infection.

Advertisement
The study had limitations: Laboratory measurements were not uniformly performed according to HIV status, and adequate fasting prior to lipoprotein testing could not be verified. The results may not be completely generalizable to uninsured persons, women or certain racial or ethnic minorities, the authors cautioned.

"Dyslipidemia, particularly hypertriglyceridemia, is more difficult to treat in patients with HIV infection than in the general population," the researchers concluded. "However, patients with HIV infection receiving NNRTI-based antiretroviral therapy and gemfibrozil had triglyceride responses similar to those in patients without HIV infection."

Back to other news for March 2009




 

Reader Comments:

Comment by: Ezana (Addis Ababa, Ethiopia) Tue., Mar. 31, 2009 at 4:29 am EDT
Dear Sirs, Madam

I have been recieving ur mail for the last four and half years. I got it very impressive & useful, besides the terms you guys are using is medical terms so if you can write some terminiology in brackets so that we can understand it better. By the way I am living with HIV since 1999 and started HART four years ago.
Keep living + Best wishes.
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement